HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis.

Abstract
Diffuse cutaneous mastocytosis is a less common but potentially life-threatening variant of childhood mastocytosis. Here we report 2 children with diffuse cutaneous mastocytosis in whom an activating somatic KIT mutation was detected. Treatment with imatinib, a KIT inhibitor, resulted in resolution of the lesions and were well tolerated by the patients.
AuthorsMarie-Anne Morren, Anne Hoppé, Marleen Renard, Maria Debiec Rychter, Anne Uyttebroeck, Patrice Dubreuil, Ludovic Martin
JournalThe Journal of pediatrics (J Pediatr) Vol. 162 Issue 1 Pg. 205-7 (Jan 2013) ISSN: 1097-6833 [Electronic] United States
PMID23069194 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2013 Mosby, Inc. All rights reserved.
Chemical References
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
Topics
  • Benzamides
  • Female
  • Humans
  • Imatinib Mesylate
  • Infant
  • Mastocytosis, Cutaneous (drug therapy)
  • Piperazines (therapeutic use)
  • Protein Kinase Inhibitors (therapeutic use)
  • Pyrimidines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: